Presentation is loading. Please wait.

Presentation is loading. Please wait.

Managing MDROs in LTCFs National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Nimalie D. Stone, MD/MS.

Similar presentations

Presentation on theme: "Managing MDROs in LTCFs National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Nimalie D. Stone, MD/MS."— Presentation transcript:

1 Managing MDROs in LTCFs National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Nimalie D. Stone, MD/MS Medical Epidemiologist for LTC GA LTC IC course Winter/Spring 2011

2 Objectives q Review basics about common bacteria which can develop antibiotic resistance in the healthcare setting q Discuss mechanisms by which antibiotic resistance emerges and spreads q Identify strategies for preventing MDRO transmission

3 Basics on Bacteria Bacteria have different characteristics that allow us to identify them in the lab Growth patterns, structure of the cell We use these characteristics to develop antibiotics Gram Stain Positive (purple) Gram Stain Negative (pink/red)

4 Common types of Bacteria Gram positive q Most are cocci, “round bacteria” q Streptococcus, Staphylococcus, Enterococcus q Clostridium difficile (C. diff) is a Gram positive rod Gram negative q Most are baccili, “rod-shaped bacteria” q Enterobacteriaceae: E coli, Klebsiella, Enterobacter, Proteus q Pseudomonas

5 Normal Bacterial Carriage People have bacteria living in and on us all the time Some live on our skin, some in our nose and throats, others in our bowels Our bodies need these bacteria to help us Some digest food/nutrients, others block bad bugs These “colonizing” bacteria aren’t harmful Only bacteria that invade our system and cause illness need to be treated

6 Antibiotics 101 q Antibiotics are drugs that treat and kill bacteria q They are grouped into classes based on their structure and activity §Narrow-spectrum target a few specific bacteria §Broad-spectrum can kill a wide variety of bacteria q Infection prevention programs track certain “bug- drug” combinations for evidence that the bacteria is getting resistant §Bacteria with resistance can cause patients to have more severe, costly infections which are harder to treat

7 Antibiotic Classes Penicillins q Examples: Penicillin, amoxicillin, ampicillin, methicillin q Penicillins can be combined with a drug to help them overcome certain bacterial resistance §Amoxicillin + Clavulante = Augmentin; §Piperacillin + tazobactam = Zosyn Cephalosporins (cousins to penicillins) q 1 st generation (more gram positive activity): Cephalexin, Cefazolin q 3 rd /4 th generation (more gram negative): Ceftriaxone, Ceftazidime

8 Antibiotic Classes (cont) Carbapenems q Examples: Imipenem, meropenem, ertapenem q Extremely broad-spectrum, among the most powerful antibiotics we currently Miscellaneous drugs with only gram positive activity: Vancomycin, linezolid, daptomycin q Vancomycin is the primary treatment for Methicillin- resistant Staphylococcus aureus (MRSA) §Oral vancomycin is ONLY used to treat C difficile; §IV Vancomycin must be used to treat all other infections q Enterococci that develop resistance to Vancomycin are called Vancomycin-resistant enterococci (VRE)

9 Antibiotic Classes (cont) Fluoroquinolones q 1 st generation (Ciprofloxacin) mostly gram neg activity, often used for UTI treatment q 2 nd /3 rd gen (Levofloxacin/Moxifloxacin) have broader activity, can cover Streptococcus pneumoniae and other respiratory/sinus bacteria Aminoglycosides q Examples: Gentamicin, Tobramycin, Amikacin q Excellent gram negative drugs – especially for urinary tract q Aren’t used as much because can be toxic to the kidneys, need to be monitored when used

10 Antibiotic Classes (cont) Miscellaneous drugs q Trimethoprim/Sulfamethoxazole (Bactrim): Considered by many to be narrow spectrum, but has Gram neg and Gram pos activity, used to treat UTIs, also good for MRSA skin infections q Azithromycin (“Z-pack”): Also considered more narrow spectrum, good for respiratory/sinus infections q Metronidazole (Flagyl): One of the main treatments for C. difficile infections

11 Mechanisms of antibiotic resistance q Production of proteins that destroy antibiotics q Beta-lactamases q Carbapenemases q Change their cell structure so antibiotics can’t bind and block their function q Reduce their antibiotic exposure q Pump drugs out q Increase cell barriers to keep drug out


13 Snapshot of resistance patterns: Facility antibiograms q A yearly summary of the common bacteria from facility cultures and their susceptibility patterns to antibiotics q Allows you to see trends in resistance over time q Ask your microbiology lab about it

14 Defining Multidrug-resistance q Resistant to treatment by several antibiotics from unrelated classes q Sometimes just one key drug resistance will define an important MDRO, for example, Methicillin-resistance in Staph aureus q Sometimes bacteria acquire resistance to several classes, often seen in gram negative rods q Cephalosporin-resistance is a big concern in bacteria like E coli/Klebsiella which often cause UTIs q Pseudomonas will be resistant to fluoroquinolones, penicillins, cephalosporins, and carbapenems

15 ABC’s of MDROs BacteriaAbbrev.Antibiotic Resistance Staphylococcus aureus MRSAMethicillin-resistant Enterococcus (faecalis/faecium) VREVancomycin-resistant Enterobacteriaceae (E coli/Klebsiella, etc) CRE (KPC) Carbapenem- resistant Pseudomonas/ Acinetobacter MDRMany drug classes

16 Staphylococcus aureus Derived from the Greek word Staphyle: “Bunch of grapes” and aureus: “gold” Part of the normal colonizing bacteria on our skin and in the nose Though it colonizes many people, it may not cause infection unless the skin gets broken or the immune system gets weak

17 Methicillin-resistant Staphylococcus aureus (MRSA): An ongoing problem First emerged in the US healthcare setting in 1968 –Outbreaks linked to transmission via healthcare workers –Prevalence in nursing homes, 20-50% Community-acquired strains are adding to the burden of infection in the healthcare setting Increasing public and legislative pressure to address the transmission of MRSA in healthcare

18 Risk Factors for Healthcare- associated MRSA infections Previous hospitalization Increased length of stay prior to onset of infection Surgery Enteral feeding Prior antibiotics Invasive devices History of MRSA colonization Residence in a long-term care facility 1. Graffunder EM & Venezia RA. J Antimic Chemo 2002;49:999-1005 2. Oztoprak, N. et al. Am J Infec Cont. 2006; 34: 1-5 3. Wertheim et al. Lancet 2005; 5: 751-62 4. Bader, M. Inf Cont Hosp Epi. 2006; 27: 1219- 1225

19 Clostridium difficile Gram positive rod which grows best without oxygen (anaerobic) C. diff has a special growth characteristic called “spores” Hard outer shells in which sleeping bacteria can survive in the environment for long periods Spores are shed in large numbers during the diarrhea caused by C diff infection (CDI)

20 Steps to C. diff Infection (CDI) Acquisition of C. difficile Antibiotic therapy Changes normal colonic bacteria C diff over grows and produces toxin

21 n More than half of healthcare associated CDI cases occur in long-term care facilities n A significant number of individuals admitted to LTC are colonized with C difficile n Up to 20% acquire it while in nursing homes n CDI is the most commonly identified cause of acute diarrheal illness in the LTC population

22 CDI risk factors causing disease Poutanen & Simor. CMAJ. 2004 171:51-8

23 Exposures and risk factors related to CDI in older adults Simor. JAGS. 2010, e publ

24 C diff. prevention challenges Spores are not killed by alcohol hand rubs; the act rubbing your hands with soap under water removes the spores Spores are resistant to common cleaners and require bleach to be effectively killed

25 Managing a resident with C diff. The goal of therapy for C diff infection is to stop the symptoms of diarrhea, abdominal upset and fever Once the diarrhea has resolved, the resident is safe to move about the facility Residents can carry C.diff in their bowels (colonized) for months after their diarrhea resolves After being treating a resident for CDI, there is NO VALUE in sending multiple C diff stool studies to see if “the infection has cleared” Often you’ll continue to get positive results which prompt unnecessary additional treatment

26 Carbapenemase producing GNRs Carbapenemases are protein enzymes that break down all penicillins, cephalosporins and carbapenems There are different types of these enzymes some found in bugs like Acinetobacter and Pseudomonas ; others found in bugs like Klebsiella The genetic material also tends to carry resistance to other antibiotic classes like fluoroquinolones and aminoglycosides What’s really scary is that the resistance genes can be easily shared to other bacteria –Especially since we have lots of gram-negative bacteria colonizing our bowels Walsh, TR. Current Opin Infect Dis 2008;21:367-71

27 States reporting Carbapenem-Resistant Enterobacteriaceae (CRE) Monitor your culture reports for Carbapenem-resistant GNRs q Widely reported in the US and specifically Georgia q Ask your referral hospitals if they have had problems q Being aware of new resistance patterns in your residents will help you prevent spread

28 q Lab examined all the Acinetobacter cultured from people at 4 local hospitals over 5 years q Classified as hospital-associated, NH-associated, or community-associated q Wanted to see how antibiotic resistance emerged in this community Case of an emerging MDRO….

29 Multidrug-resistance emerged quickly q Over 5 year period, antibiotic resistance increased dramatically q In the last 2 years of the study pan-resistant bacteria emerged q Culture sources: Respiratory secretions (56%); Wounds (22%); Urine (12%) Sengstock DM, et al. Clin Infect Dis. 2010 50(12): 1611-1616

30 Healthcare facilities are the source of MDROs Sengstock DM, et al. Clin Infect Dis. 2010 50(12): 1611-1616 q All the highly resistant bacteria were coming from patients in the hospital or those in the nursing homes – NOT from people living at home

31 MDROs in the healthcare setting DEVELOPMENT q Antibiotic pressure q Most common predictor of antibiotic resistance is prior antibiotic use q Device utilization q Biofilm formation on central lines, urinary catheters, etc. SPREAD q Patient to patient transmission via healthcare workers q Environmental / equipment contamination q Role of colonization pressure on acquisition

32 Resistance from antibiotic pressure q At first most of the bacteria can be killed by the drug (green) q But, once they are wiped out, the resistant bugs take over (red)

33 Antibiotic use drives resistance Johnson et al. Am J. Med. 2008; 121: 876-84

34 Biofilm formation on device surfaces q Biofilm: An collection of bacteria within a sticky film that forms a community on the surface of a device

35 Biofilm on an indwelling catheter Tenke, P et al. World J. Urol. 2006; 24: 13-20

36 Resistance develops within biofilms q Bacteria within a biofilm are grow every differently from those floating around freely q These changes in their growth make our antibiotics less effective q Antibiotics can’t penetrate the biofilm to get to the bacteria q This leads to much less drug available to treat the bugs q Bacteria within the biofilm can talk to each other and share the traits that allow some to be resistant q Over time more and more of them become resistant as well Tenke, P et al. World J. Urol. 2006; 24: 13-20

37 Improved Patient Outcomes Associated with Hand Hygiene Ignaz Philipp Semmelweis (1818-1865) Chlorinated Lime Hand Antisepsis Adapted from CDC. Prevent Antimicrobial Resistance: A Campaign for Clinicians. April 2002.


39 Bacterial contamination of HCW hands prior to hand hygiene in a LTCF Mody L, et al. InfectContHospEpi. 2003; 24: 165-71 q Gram negative bacteria were the most common bugs cultured from hands of staff q Most Gram neg. bacteria live in the bowls or colonize the urine!!!

40 Hand Hygiene q Most effective and least costly means of preventing the transmission of MDROs q Yet, compliance still ranges between ~30- 60%

41 Alcohol-based hand rub improves compliance and decontamination Mody L, et al. InfectContHospEpi. 2003; 24: 165-71

42 Decreased MRSA infections associated with increased hand hygiene compliance Pittet, D et al.Lancet 2000;356:1307-12


44 The invisible reservoir of MDROs Image from Abstract: The Risk of Hand and Glove Contamination after Contact with a VRE (+) Patient Environment. Hayden M, ICAAC, 2001, Chicago, IL. X marks the locations where VRE was isolated in this room Slide courtesy of Teresa Fox, GA Div PH

45 Duration of environmental contamination by MDROs

46 Colonization pressure on risk of acquisition q Colonization pressure: Presence of other MDRO carriers on a unit will increase the risk of MDRO acquisition to a non-carrier close by q Studies have demonstrated the impact of colonization pressure on acquisition of MRSA, VRE and CDI q Both asymptomatic carriers (colonized) and actively infected individuals can be a source for transmission (spread) on a unit Williams VR et al. Am J Infect Control. 2009 Mar;37(2):106-10 Bonten MJ et al. Arch Intern Med. 1998 May 25;158(10):1127-32. Dubberke ER et al. Arch Intern Med. 2007 May 28;167(10):1092-7

47 Colonization pressure: C.diff example Unit A Fewer patients with active CDI =lower risk of acquiring CDI Unit B More patients with active CDI =higher risk of acquiring CDI CDI pressure =1 × days in unit CDI pressure =5 × days in unit Dubberke ER, et al. Clin Infect Dis. 2007;45:1543-1549. Dubberke ER et al. Arch InternMed.2007;167(10):1092-7

48 Key MDRO Prevention Strategies q Assessing hand hygiene practices q Implementing Contact Precautions q Recognizing previously colonized patients q Rapidly reporting MDRO lab results q Strategically place residents based on MDRO risk factors q Careful device utilization q Antibiotic stewardship q Inter-facility communication

49 Assessing Hand Hygiene Hand hygiene should be a cornerstone of prevention efforts As part of a hand hygiene intervention, consider: –Ensuring easy access to soap and water/alcohol- based hand gels –Observation of practices - particularly around high- risk situations (before and after contact with colonized or infected patients) –Feedback – “Just in time” feedback if failure to perform hand hygiene observed

50 Implementing Contact Precautions Involves use of gown and gloves for patient care –Don equipment prior to room entry –Remove prior to room exit Selective roommate placement for MDRO colonized/infected individuals Observation of practices - particularly around high-risk situations Use of dedicated non-essential items may help decrease transmission due to contamination –Blood pressure cuffs; Stethoscopes; IV poles and pumps

51 Recognizing Prior Colonization q Individuals can be colonized with MDROs for months q Being able to identify previously colonized or infected individuals allows for application of appropriate interventions in a timely fashion q Being an MDRO carrier should not prevent a resident from being admitted to a LTCF, q Knowledge allows us to plan for them to have the safest care q For every resident carrying an MDRO that we know about, there are probably 3 others we don’t know

52 Strategic placement of residents based on risk factors Base new roommate assignments on resident characteristics –Wounds, devices, current antibiotics, incontinence are all risks for being an MDRO carrier or acquiring a new MDRO –Try to avoid placing two high risk residents together Don’t necessarily change stable room assignments just because of a new culture result unless it now poses new risk –Roommates who’ve been together for a long time have already had opportunity to share organisms in the past (even if you only learned about it recently)

53 Prompt Recognition of MDROs in Laboratory Reports Facilities should have a mechanism for rapidly communicating positive MDRO lab results to clinical area –Allows for rapid initiation of interventions on newly identified MDRO carriers Consider implementing precautions while waiting for results from the lab if an MDRO is possible –For example, contact precautions for a resident with diarrhea while waiting for results of a C diff stool study

54 Careful Device Utilization Know the population of residents with indwelling medical devices –May require focused infection surveillance Continually assess the ongoing need for devices –Develop a bladder protocol for urinary catheter removal –Resist the temptation to retain IV lines beyond the duration of treatment “just in case” Ensure staff are comfortable and trained on handling/maintenance of medical devices

55 Antibiotic Stewardship Careful antibiotic use is a critical component in the control of MDROs Know the frequency/indications for antibiotic use by medical providers in your facility –Apply criteria to assess utilization in a standard way Develop standard protocols for communicating concerns and assessing residents who are suspected to have an infection between nursing and medical staff –Ensure documentation of signs/symptoms is complete

56 Case study on care transitions q A LTC resident was transferred to a local ED with worsening lower extremity swelling and shortness of breath q Resident’s history included coronary heart disease, Diabetes with neuropathy, enlarged prostate q Diagnosed with worsening heart failure admitted to ICU for cardiac monitoring and fluid management q A urinary catheter was placed at the time of admission and a specimen was sent for UA/culture in ED. q Based on the UA, the patient was started on antibiotics

57 Case study (continued) q After treatment for heart failure and the positive urine culture, the resident was discharged backed to the LTC facility with the catheter in place. q Prior to removing the urinary catheter a repeat culture was sent which grew VRE q A second course of antibiotics was initiated q Two weeks later the resident developed diarrhea and fever q Stool sample was positive C. Diff toxin test.

58 Issues raised by our case q Is the practice of screening urine cultures on admission a valuable strategy? q What are the pros/cons q Did the resident continue to need the urinary catheter once the CHF was managed? q How is resident functionality communicated at time of transfer q How are antibiotics used in both acute/LTC facilities in this shared population? q Who is accountable for the complications of antibiotic use?

59 Inter-facility Communication Mechanism for communicating MDRO carriage and other risk factors at time of transfer between facilities Critical components: –MDRO history of current infection or carriage –Device utilization –Current antibiotic treatments (indication/duration) –Bedside care issues (wounds, continence, etc)


61 Summary of Prevention Strategies q Assessing hand hygiene practices q Implementing Contact Precautions q Recognizing previously colonized patients q Rapidly reporting MDRO lab results q Strategically place residents based on MDRO risk factors q Careful device utilization q Antibiotic stewardship q Inter-facility communication

62 q Describes the impact of regionally implemented infection control strategies to address VRE emerging in the Siouxland region of Iowa, Nebraska and S. Dakota q Three annual point prevalence surveys (active surveillance) for VRE among patients/residents in participating acute/long-term care facilities Story of Success…

63 Ostrowsky BE et al. New Eng J Med 2001 344: 1427-1433 IC practice guidelines for facilities

64 Ostrowsky BE et al. New Eng J Med 2001 344: 1427-1433 VRE prevalence decreased following prevention intervention q 32 Facilities participated in 1997 and 1998 (4 acute/ 28 LTC) vs. 30 in1999 (4 acute/ 26 LTC) q Overall 85%-89% of eligible patients/ residents cultured each year § 52-59% in acute care § 90-95% in LTC

65 Critical message about collaboration Ostrowsky BE et al. New Eng J Med 2001 344: 1427-1433

66 Thank you!! National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Email: with questions/comments

Download ppt "Managing MDROs in LTCFs National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Nimalie D. Stone, MD/MS."

Similar presentations

Ads by Google